Search clinical trials for: GS-9411

Total 495 results

Gilead Sciences

Withdrawn

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis | Mucociliary Clearance

Australia
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Completed

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis

Australia
Gilead Sciences

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Recruiting

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Solid Tumors

Australia, United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Combination Therapy for Chronic Hepatitis C Infection

Hepatitis C, Chronic

United States
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Gilead Sciences

Terminated

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Chronic Hepatitis C

United States, Australia, Canada, New Zealand
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Germany
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand
Gilead Sciences

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

HCV Infection

United States, Netherlands, Germany
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States, France
Bayer

Completed

A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome

Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia

Germany
Gilead Sciences

Completed

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Genital Warts

United States
Gilead Sciences
Ono Pharmaceutical Co. Ltd; Galapagos NV

Completed

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Sjogren's Syndrome

United States, Spain, United Kingdom, Poland
Infant Bacterial Therapeutics

Active, not recruiting

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Necrotizing Enterocolitis

United States, Spain, Israel, United Kingdom, France, Poland, Romania, Bulgaria, Hungary, Serbia
Infant Bacterial Therapeutics

Completed

IBP-9414 for the Prevention of Necrotizing Enterocolitis

Necrotizing Enterocolitis

United States
Bayer

Completed

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

Functional Gastrointestinal Disorders

Germany
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gesynta Pharma AB
CTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden AB

Completed

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Pharmacokinetic

Sweden
Ahon Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation

Lung Cancer

China
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Bayer

Completed

Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus

Functional Gastrointestinal Disorders

Germany
Bristol-Myers Squibb

Completed

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. (MDX1411-01)

Kidney Cancer

United States
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

RSV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus

United States, Canada
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
Bayer

Completed

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Irritable Bowel Syndrome

Germany
Gilead Sciences

Completed

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Korea, Republic of
Gilead Sciences

Terminated

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Gilead Sciences

Completed

Study of the Effect of GS-6615 in Subjects With LQT-3

Long QT Syndrome

United States
Gilead Sciences

Terminated

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Chronic Obstructive Pulmonary Disease | Cystic Fibrosis

United States
Gilead Sciences

Completed

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Germany, United States, Australia, United Kingdom, Canada, France, New Zealand
Neuron23 Inc.

Recruiting

A Study to Assess NEU-411 in Healthy Participants

Healthy

New Zealand
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects (SUVN-911)

Depressive Disorder, Major

United States
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, New Zealand
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

HCV Infection

United States, Germany, New Zealand
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

HCV Infection

United States, New Zealand, Germany
Gilead Sciences

Completed

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

Inflammatory Disease

United States, New Zealand, Germany
Gilead Sciences

Completed

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Long QT Syndrome

United States, Romania, Moldova, Republic of
Gilead Sciences

Completed

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Ischemic Heart Disease

United States

3

Subscribe